CorMedix Inc. Announces FDA Approval of DefenCath® to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis PatientsGlobeNewsWire • 11/15/23
CorMedix Inc. Reports Third Quarter and Nine Month 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/14/23
CorMedix Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on November 14, 2023GlobeNewsWire • 11/02/23
CorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare ConferenceGlobeNewsWire • 09/26/23
CorMedix Inc. Announces Publication of Phase 3 LOCK IT-100 Study Data in the Clinical Journal of The American Society of NephrologyGlobeNewsWire • 09/08/23
CorMedix Inc. to Present at the H.C. Wainwright Annual Global Investment ConferenceGlobeNewsWire • 09/06/23
CorMedix Inc. Announces Issuance of U.S. Patent Covering Lead Product DefencathGlobeNewsWire • 08/30/23
CorMedix Inc. Reports Second Quarter and Six Month 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/08/23
CorMedix Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 06/29/23
CorMedix Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 06/28/23
CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCathGlobeNewsWire • 06/21/23
Cormedix Inc. Announces Strategic Initiative With Boston Medical Center to Reduce Health Disparities in Patients at Risk for Bloodstream InfectionsGlobeNewsWire • 06/15/23
CorMedix Inc. To Report First Quarter 2023 Financial Results and Provide a Corporate Update on May 15, 2023GlobeNewsWire • 05/08/23